CURRICULUM VITAE

Mario Capasso

ORCID ID: orcid.org/0000-0003-3306-1259
URL for web site: https://www.docenti.unina.it/mario.capasso

(redatto ai sensi degli Art. 46 e 47 del D.P.R. 28.12.2000, n. 445)

Il sottoscritto Mario Capasso, nato a Napoli il 07/04/1977 residente in Napoli Corso Amedeo di Savoia 182, consapevole, ai sensi dell'art. 76 del D.P.R. 445/2000, che dichiarazioni mendaci, formazione o uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali in materia,

DICHIARA:

TITOLI di STUDIO

- 26/10/2001: **Laurea in Biotecnologie**, Università di Napoli Federico II con **voto: 110/110**.
- 22/01/2007: **Dottorato di Ricerca** in Medicina Molecolare dell'adulto e del Bambino, Università degli Studi di Foggia, con la **votazione di Ottimo**.

ESPERIENZE LAVORATIVE

- 2002: Borsista presso il centro di ricerca ConSDABI, Circello (BN).
- 2003: Borsista presso il Dipartimento di Biochimica e Biotecnologie Mediche (DBBM), Università di Napoli Federico II.
- 2004-2006: PhD student presso l'Istituto di ricerca CEINGE Biotecnologie Avanzate, Napoli.
- 2007-2008: Post doc al Chindren's Hospital of Philadelphia, USA.
- 2009-2010: Borsista presso l'Istituto di ricerca CEINGE Biotecnologie Avanzate, Napoli
- 2009 ad oggi: Supervisore del Centro di Consulenza Biostatistica presso il CEINGE Biotecnologie Avanzate.
- 2011 ad oggi: Ricercatore a tempo determinato (Legge 04.11.2005 n. 230), Università di Napoli Federico II, (MED/03, Genetica medica), Dipartimento di Medicina Molecolare e Biotecnologie Mediche. Attività di ricerca svolta presso l'Istituto di ricerca CEINGE Biotecnologie Avanzate, Napoli .
- 2013 ad oggi: Membro del Gruppo di Lavoro dell'Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) in Lab.
- 2018 ad oggi Professore Associato Dipartimento di Medicina Molecolare e Biotecnologie Mediche. Attività di ricerca svolta presso l'Istituto di ricerca CEINGE Biotecnologie Avanzate, Napoli .

ATTIVITÀ SCIENTIFICA

Scientific Output

1) 62 pubblicazioni scientifiche (2 Nat Genet, 2 Nature, 1 NEJM) in international peer-reviewed journals dei quali 12 come primo autore and 9 come ultimo autore (Citazioni totali: 1581. H-index: 22)

2) 10 seminari su invito (in 8 Istituti di ricerca nazionali and 2 internazionali)

3) 13 inviti come relatore a congressi (7 nazionali and 6 internazionali)

4) 4 inviti come relatore a corsi di formazione concernenti la genetica medica
5) 7 progetti finanziati in corso 5 conclusi
6) 3 Premi ricevuti
Gli indici riguardanti le pubblicazioni sono stati estratti da SCOPUS
Descrizione dell'attività di ricerca

- Mario Capasso dal 2003 si interessa dello studio delle **basi genetiche delle malattie multifattoriali e monogeniche**. Grazie a partecipazione a corsi di formazione internazionali e nazionali e all'esperienza di laboratorio, ha acquisito le conoscenze per l'identificazione dei "geni malattia", specializzandosi principalmente in analisi di **statistica medica e genetica**, **di associazione genetiche** tipo **studi caso-controllo, di linkage, di meta-analisi, di dati di microrray e di deep sequencing**. Lo scopo della sua ricerca è di ampliare le conoscenze circa le basi genetiche e biologiche dei tumori pediatrici e delle malattie complesse che possono essere trasferiti nella pratica clinica, mediante due obiettivi: a) Identificazione dei fattori genetici mediante analisi del genoma su larga scala (deep sequencing e genome-wide association studies); b) Caratterizzazione funzionale del ruolo dei fattori genetici nell'alterare i meccanismi molecolari che sottostanno alle malattie complesse inclusi i tumori mediante tecniche di genomica funzionale, biologia cellulare e molecolare.

Responsabile di facility

- Mario Capasso dal 2009 dirige il Centro di Consulenza Biostatistica del CEINGE fornendo assistenza ai gruppi di ricerca per analisi dei dati di progetti di ricerca in medicina, genomica, genetica di popolazione.

SUPERVSIONE DI LAURENDI, NEO-LAUREATI, POST-DOC

- 2009-2011: Giuseppe Petrosino, Postgraduate fellowship, Posizione successiva: PhD student, Stazione Zoologica Anton Dohrn, Napoli, Italia
- 2010-2013: Francesca Totaro, PhD student, Posizione successiva: Postdoctoral fellowship at The Center for Advanced Biomaterials for Healthcare at CRIB, Napoli, Italia
- 2013-2015: Piero Pignataro, Postgraduate fellowship, Posizione successiva: Cytogenetics and Cytogenomic Center, University of Naples Federico II, Napoli, Italia
- 2015: Andrea Cirino, Postgraduate fellowship, Posizione successiva: PhD student at University of Naples Federico II, Napoli, Italia
- 2013-2014: Francesco Maria Calabrese, Postdoctoral fellowship, Posizione successiva: Genome Science Department Washington University, Seattle, USA
- 2014-2016: Lucia Pezone, PhD student, CEINGE Biotecnologie Avanzate, Napoli, Italia
- 2014 – ad oggi: Alessandro Lasorsa, Postgraduate fellowship
- 2010 -– ad oggi: Flora Cimmino, Postdoctoral fellowship
- 2016 – ad oggi: Alessandro Testori, Postdoctoral fellowship
- 2015 – ad oggi: Daniela Formicola, Postdoctoral fellowship
- 2015– ad oggi: Antonella Cardinale, Studente Laurea Magistrale in Biotecnologie and Postgraduate fellowship
- 2016 - ad oggi :Giusy Vignola, Studente Laurea Magistrale in Biotecnologie

ATTIVITÀ DI REVISORE (Lavori scientifici e progetti di ricerca)

- Riviste scientifiche: GUT, Journal of Human Genetics, PlosOne, Carcinogenesis, BMC Cancer, British of Journal Cancer, Journal of the American Society of Nephrology, Cancer Research, Cancer Discovery
- Attività di revisore per i progetti dell'Austrian Science Fund (WFW).
- 2013 Review panel member, Austrian Science Fund (WFW), Austria
- 2015 Review panel member, ERA-NET: TRANSCAN-2, Comunità Europea
- 2016 Advisory Board: 8th Annual Next Generation Sequencing Congress & 3rd Annual Single Cell Analysis Congress 2016 by Oxford Global
- 2016 ad oggi **Editorial Board Member del panel: Genetics and Genomics della rivista scientifica, : "Scientific Reports"**
- 2017 Advisory Board: Annual Next Generation Sequencing Congress & Annual Single Cell Analysis Congress 2017 by Oxford Global
- 2017 Review panel member, Bando competitivo Fondazione di Sardegna
- 2018 Review panel member, Paediatric Research Project Grant 2018, Iralnda

PROGETTI FINANZIATI CONCLUSI

1. 01/01/2011-31/12/2013: MIUR – FIRB Futuro in ricerca, ID: RBFR08DWQ3, Budget: 238,400 €, **Principal Investigator**, "A multiple methodological approach to identify susceptibility genes to neuroblastoma clinically aggressive".
2. 01/01/2011-31/12/2014: AIRC – Italian Association for Cancer Research, ID: 10537, Budget: 150,000 €, **Principal Investigator**, "High-throughput sequence analysis of the tyrosine kinome in neuroblastoma".
3. 01/01/2011-31/12/2011: Fondazione Italiana per la Lotta al Neuroblastoma, Budget: 37,000 €, **Principal Investigator,** "Discovering interactions between BARD1 and other candidate genes in sporadic neuroblastoma".
4. 01/01/2012-31/12/2014: Fondazione Italiana per la Lotta al Neuroblastoma, Budget: 117,000 €, **Principal Investigator,** "Using genome-wide approaches to improve diagnosis, prognosis and treatment of neuroblastoma".
5. 01/01/2014-31/12/2016: Fondazione Italiana per la Lotta al Neuroblastoma, Budget: 405,000 €, **Co-Investigator**, "Fast development of a personalized medicine of high-risk neuroblastoma by drug repositioning and genome-based targeting".
6. 03/11/2014-03/11/2018: Ministero della Salute, ID: GR-2011-02348722, Budget: 336,007.76 €, **Principal Investigator**, "Genome-wide analyses to improve prognostic and therapeutic strategies in neuroblastoma".
7. 23/01/2017-23/1/2019: progetto STAR Linea 1 2016, Budget: 94,000 €, **Principal Investigator**, "Identification and characterization of shared susceptibility loci for neural crest cell-derived tumors".
8.

PROGETTI FINANZIATI IN CORSO

1. 01/04/2013-01/04/2021: NIH, ID: R01 CA124709-06, (USA), **Co-Investigator**, "The Genetic Basis of Neuroblastoma Tumorigenesis".

2. 01/01/2017-31/12/2019: AIRC – Italian Association for Cancer Research, ID: 19255, **Principal Investigator**, "Understanding the shared genetic and biological basis among neural crest cells-derived tumors".
3. 01/09/2017-01/09/2020: OPEN l'Associazione Oncologia Pediatrica e Neuroblastoma, **Principal Investigator**, "La biopsia liquida per la cura dei bambini con tumori solidi pediatrici".
4. 01/01/2018-31/12/2021: Ministero della Salute, GR-2016-02364546, **Co-Investigator**, "Advanced therapy medicinal product based on CD30-specific chimeric antigen receptor (CAR) T cells for treatment of patients with relapsed/refractory CD30+ lymphomas".
5. 01/01/2020-31/12/2022: Fondazione Italiana per la Lotta al Neuroblastoma, **Principal Investigator**, "GENEDREN".

PREMI E RICONOSCIMENTI

1. 27/02/2008: vincitore del premio "Patient-Oriented Research award" all'"Annual Children's Hospital of Philadelphia Poster Day", Philadelphia (USA).
2. 05/03/2010: vincitore del premio "Guido Paolucci International Award" Accademia delle Scienze di Bologna, Italy, miglior contributo scientifico di argomento oncologico pediatrico pubblicato in lingua inglese su una rivista scientifica censita dal JCR durante il 2009.
3. 20/05/2011: Workshop AIEOP...in Lab Award, Miglior lavoro scientifico in pediatria oncologica.

ORGANIZZAZIONE DI CONGRESSI SCIENTIFICI

2015: IV Workshop AIEOP in Lab. Napoli.

RELATORE SU INVITO A CONGRESSI INTERNAZIONALI

1. 22/05/2014: 3rd World Genetics & Genomics Online Conference. Titolo: Genome-wide association study to understand the genetics and biology of neuroblastoma.
2. 10/10/2014: 19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine. Athens, Greece. Titolo: Genome-wide association study to understand the genetics and biology of neuroblastoma
3. 20/10/2014: 2nd qPCR & Digital PCR Congress, London, UK. Titolo: qPCR methods to improve prediction of cancer prognosis.
4. 13/09/2015: 7th Annual Next Generation Sequencing Congress & 3rd Annual Single Cell Analysis Congress. Londra. Titolo: Whole Exome And Deep Targeted Sequencing Of Clinically Aggressive Neuroblastoma.
5. 25/04/2016: The Game of Epigenomics. Dubrovnik. Titolo: Whole Exome And Deep Targeted Sequencing Of Clinically Aggressive Neuroblastoma.
6. 25/10/2017: SIOPEN Research Symposium. Berlin. Titolo: Identification of ultra-HR patients using gene expression profiling of Kinome.

RELATORE SU INVITO A CONGRESSI NAZIONALI

1. 13/03/2006: Genetics of multifactorials traits. Napoli. Titolo: Genetics of Chronic Hepatitis.
2. 18/11/2006: Pharmacogenetics, Napoli. Titolo: The IFN experience, Pharmacogenetics tools in paediatric research.
3. 06/06/2010: XXXVI National Congress AIEOP. Pisa. Titolo: New genes in solid tumors.

4. 21/11/2012: XV National Congress SIGU. Sorrento. Titolo: Implication of mtDNA mutations in neuroblastoma.
5. 10/05/2013: Rehabilitation in Neuro-Oncology. Napoli. Titolo: Genetics of Neuroblastoma
6. 15/09/2015: IV Workshop AIEOP in Lab. Napoli. Titolo: La genomica clinica in oncologia pediatrica.
7. 16/12/2018. Pediatric Surgical Oncology Today. Ospedale Bambino Gesù, Roma. Titolo: Genetics of Neuroblastoma.

RELATORE SU INVITO A CORSI DI FORMAZIONE IN GENETICA MEDICA

1. 24/02/2017: Medicina Del Futuro o Futuro della Medicina, Pavia. Titolo: NGS of Neuroblastoma.
2. 04/04/2017: Corso di perfezionamento "Citogenetica e Citogenomica", Napoli. Titolo: Clinical Genomics of Pediatric Cancers.
3. 26/01/2018: V Corso di Formazione in Genetica Medica. Titolo: Neoplasia dell'età pediatrica.
4. 10/04/2018: Corso di perfezionamento Citogenetica e Citogenomica, Napoli. Titolo: Clinical Genomics of Pediatric Cancers.
5. 10/4/2019: WorkShop: Genome editing: a star is born, Firenze. Titolo: Genome editing to study the noncoding variants impact on carcinogenesis
6. 09/9/2019: NGS in Clinical Settings, Napoli. Titolo: NGS: chiamata delle varianti, annotazione e interpretazione
7. 20/9/2019 Corso avanzato di Cito-Genetica costituzionale e acquisita. Grandangolo in Genetica Medica. Roma. Titolo: Genome editing nello studio delle varianti non codificanti: impatto nella carcinogenesi

SEMINARI SU INVITO

1. 07/12/2007: Chalk Talk, Children's Hospital of Philadelphia, Philadelphia, USA. Titolo: Genome-wide association study of Neuroblastoma.
2. 22/05/2008: Post Doc Seminar Series, Children's Hospital of Philadelphia, Philadelphia, USA. Titolo: A Genome-wide Association Study Shows That Common Alleles of BRCA1-associated RING Domain Protein (BARD1) Predispose to High-risk Neuroblastoma.
3. 21/06/2011: Seminari Interdipartimentali, Università di Napoli Federico II. Titolo: Discovering genetic bases of neuroblastoma.
4. 15/03/2013: Job Seminar, Università di Trento. Titolo: Genome-wide approaches to unravel the genetic basis of neuroblastoma and improve the prognosis prediction.
5. 20/05/2013: Seminari Interdipartimentali, Università di Napoli Federico II. Titolo: Genome-wide approaches to unravel the genetic basis of neuroblastoma and improve the prognosis prediction.
6. 12/10/2016: Ospedale Bambino Gesù di Roma. Titolo: The genomic basis of neuroblastoma.
7. 06/04/2016: Università degli Studi d Padova. Titolo: The genomic basis of neuroblastoma.
8. 28/04/2017: Scuola di Specializzazione Genetica Medica. Firenze. Title: The genetic basis of neuroblastoma.
9. 24/07/2017: CNR, ISTITUTO DI RICERCA GENETICA E BIOMEDICA (IRGB). Cagliari. Titolo: The genetic basis of neuroblastoma.

10. 14/11/2017: IRCCS SDN, Istituto di Ricerca Diagnostica e Nucleare. Titolo: Discovery genomic alterations of neuroblastoma to develop a personalized drug therapy

CORSI DI FORMAZIONE INTERNAZIONALI

- Dal 30/03/2005 al 02/04/2005: "*1st Course in Statistical Genetic Analysis of Complex Phenotypes*", European School of Genetic Medicine, Bologna University Residential Centre (Italia).
- Dal 03/05/2006 al 05/05/2006: "*2nd Course in Statistical Genetic Analysis of Complex Phenotypes*" European School of Genetic Medicine, Bologna University Residential Centre (Italia).
- Dal 04/06/2007 al 08/06/2007: *"Basic Gene Mapping/Linkage Course"*, Rockefeller University, New York (USA).
- Dal 10/12/2007 al 14/12/2007: "*Advanced Gene Mapping Course*", Rockefeller University, New York (USA).
- Dal 24/09/2012 al 28/09/2012 "*Genomic Analysis of Complex and Monogenic Disorders"* Cagliari (Italia).
- Dal 29/10/2012 al 03/11/2012: EMBO Practical Course: "*Analysis of High-Throughput Sequencing Data"* Wellcome Trust Genome Campus, Hinxton, UK

CORSI DI FORMAZIONE NAZIONALI

- Dal 24/10/2005 al 27/10/2005: "*Statistical analysis for scientific research-SRS2*", SPSS, al StarHotel Terminus, Napoli.
- Dal 05/12/2005 al 07/12/2005: secondo corso di formazione "*Statistical analysis for scientific research-SRS3*", SPSS, al StarHotel Terminus, Napoli.
- Dal 09/06/2003 al 11/06/2003: "*Basic Genetic Epidemiology*", all'Istituto Superiore di Sanità di Roma

PUBBLICAZIONI

1. Del Vecchio A, Laforgia N, **Capasso M**, Iolascon A, Latini G. The role of molecular genetics in the pathogenesis and diagnosis of neonatal sepsis. Clin Perinatol. 2004 Mar;31(1):53-67. Review.
2. Dufour C, **Capasso M**, Svahn J, Marrone A, Haupt R, Bacigalupo A, Giordani L, Longoni D, Pillon M, Pistorio A, Di Michele P, Iori AP, Pongiglione C, Lanciotti M, Iolascon A. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. Br J Haematol. 2004 Sep;126(5):682-5.
3. Svahn J, **Capasso M**, Lanciotti M, Marrone A, Haupt R, Bacigalupo A, Pongiglione C, Boschetto L, Longoni D, Pillon M, Pistorio A, Di Michele P, Iori AP, Calvillo M, Locasciulli A, Menna G, Riccardi R, Ramenghi U, Dufour C, Iolascon A. The polymorphisms -318C>T

in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian population. Bone Marrow Transplant. 2005 Mar;35 Suppl 1:S89-92.

4. Barone M, Spano D, D'Apolito M, Centra M, Lasalandra C, **Capasso M**, Di Leo A, Volinia S, Arcelli D, Rosso N, Francavilla A, Tiribelli C, Iolascon A. Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. Mol Med. 2006 Apr-Jun;12(4-6):115-23.
5. Persico M, **Capasso M**, Persico E, Masarone M, Renzo Ad, Spano D, Bruno S, Iolascon A. Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol. 2006 Dec;45(6):779-85.
6. **Capasso M**, Avvisati RA, Piscopo C, Laforgia N, Raimondi F, de Angelis F, Iolascon A. Cytokine gene polymorphisms in Italian preterm infants: association between interleukin-10 -1082 G/A polymorphism and respiratory distress syndrome. Pediatr Res. 2007 Mar;61(3):313-7.
7. Cimmino F, Spano D, **Capasso M**, Zambrano N, Russo R, Zollo M, Iolascon A. Comparative proteomic expression profile in all-trans retinoic acid differentiated neuroblastoma cell line. J Proteome Res. 2007 Jul;6(7):2550-64.
8. Persico M, **Capasso M**, Persico E, Svelto M, Russo R, Spano D, Crocè L, La Mura V, Moschella F, Masutti F, Torella R, Tiribelli C, Iolascon A. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology. 2007 Oct;46(4):1009-15.
9. Persico M, **Capasso M**, Russo R, Persico E, Crocè L, Tiribelli C, Iolascon A. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut. 2008 Apr;57(4):507-15.
10. Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, Asgharzadeh S, Attiyeh EF, Diskin SJ, Laudenslager M, Winter C, Cole KA, Glessner JT, Kim C, Frackelton EC, Casalunovo T, Eckert AW, **Capasso M**, Rappaport EF, McConville C, London WB, Seeger RC, Rahman N, Devoto M, Grant SF, Li H, Hakonarson H. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008 Jun 12;358(24):2585-93.
11. Spano D, Cimmino F, **Capasso M**, D'Angelo F, Zambrano N, Terracciano L, Iolascon A. Changes of the hepatic proteome in hepatitis B-infected mouse model at early stages of fibrosis. J Proteome Res. 2008 Jul;7(7):2642-53.
12. **Capasso M**, Russo R, Iolascon A. Farmacogenomica e farmacogenetica: profilo genetico individuale e risposta ai farmaci. Minerva Pediatr 2009;61:615-7 (PMID: 19935509).

13. Persico M, Russo R, Persico E, Svelto M, Spano D, Andolfo I, La Mura V, **Capasso M**, Tiribelli C, Torella R, Iolascon A. SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. Clin Chem Lab Med. 2009;47(10):1217-25.
14. Elia J, **Capasso M**, Zaheer Z, Lantieri F, Ambrosini P, Berrettini W, Devoto M, Hakonarson H. Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: suggestive association signals in ADRA1A. Psychiatr Genet. 2009 Jun;19(3):134-41.
15. **Capasso M**, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, Mosse YP, Kim C, Diskin SJ, Cole KA, Bosse K, Diamond M, Laudenslager M, Winter C, Bradfield JP, Scott RH, Jagannathan J, Garris M, McConville C, London WB, Seeger RC, Grant SF, Li H, Rahman N, Rappaport E, Hakonarson H, Maris JM. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009 Jun;41(6):718-23.
16. **Capasso M**, Ayala F, Russo R, Avvisati RA, Asci R, Iolascon A. A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population. J Cancer Res Clin Oncol. 2009 Dec;135(12):1799-807.
17. Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, **Capasso M**, Tiribelli C, Iolascon A. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med. 2010 Mar;16(3-4):102-15.
18. **Capasso M**, Ayala F, Avvisati RA, Russo R, Gambale A, Mozzillo N, Ascierto PA, Iolascon A. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. J Hum Genet. 2010 Aug;55(8):518-24.
19. **Capasso M**, Diskin SJ. Genetics and genomics of neuroblastoma. Cancer Treat Res. 2010;155:65-84.
20. Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, Schnepp RW, Diamond M, Bosse K, Mayes PA, Glessner J, Kim C, Frackelton E, Garris M, Wang Q, Glaberson W, Chiavacci R, Nguyen L, Jagannathan J, Saeki N, Sasaki H, Grant SF, Iolascon A, Mosse YP, Cole KA, Li H, Devoto M, McGrady PW, London WB, **Capasso M**, Rahman N, Hakonarson H, Maris JM. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011 Jan 13;469(7329):216-20.
21. Nguyen le B, Diskin SJ, **Capasso M**, Wang K, Diamond MA, Glessner J, Kim C, Attiyeh EF, Mosse YP, Cole K, Iolascon A, Devoto M, Hakonarson H, Li HK, Maris JM. Phenotype

restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet. 2011 Mar;7(3):e1002026.

22. Andolfo I, Petrosino G, Vecchione L, De Antonellis P, **Capasso M**, Montanaro D, Gemei M, Troncone G, Iolascon A, Orditura M, Ciardiello F, De Vita F, Zollo M. Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. BMC Cancer. 2011 Apr 11;11:126.
23. Russo R, **Capasso M**, Paolucci P, Iolascon A. Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. Eur J Clin Pharmacol. 2011 May;67 Suppl 1:17-27.
24. Russo R, Gambale A, Esposito MR, Serra ML, Troiano A, De Maggio I, **Capasso M**, Luzzatto L, Delaunay J, Tamary H, Iolascon A. Two founder mutations in the SEC23B gene account for the relatively high frequency of CDA II in the Italian population. Am J Hematol. 2011 Sep;86(9):727-32.
25. Spadaro G, D'Orio C, Genovese A, Galeotafiore A, D'Ambrosio C, Di Giovanni S, Vitale M, **Capasso M**, Lamberti V, Scaloni A, Marone G, Zambrano N. Proteomic analysis of sera from common variable immunodeficiency patients undergoing replacement intravenous immunoglobulin therapy. J Biomed Biotechnol. 2011;2011:706746.
26. Daniele A, De Rosa A, De Cristofaro M, Monaco ML, Masullo M, Porcile C, **Capasso M**, Tedeschi G, Oriani G, Di Costanzo A. Decreased concentration of adiponectin together with a selective reduction of its high molecular weight oligomers is involved in metabolic complications of myotonic dystrophy type 1. Eur J Endocrinol. 2011 Dec;165(6):969-75.
27. Liguori L, Andolfo I, De Antonellis P, Aglio V, Di Dato V, Marino N, Orlotti NI, De Martino D, **Capasso M**, Petrosino G, Schramm A, Navas L, Tonini GP, Eggert A, Iolascon A, Zollo M. The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. Cell Cycle 2012 Feb; 11:3, 569-581.
28. Daniele A, De Rosa A, Nigro E, Scudiero O, **Capasso M**, Masullo M, de Laurentiis G, Oriani G, Sofia M, Bianco A. Adiponectin oligomerization state and adiponectin receptors airway expression in chronic obstructive pulmonary disease. Int J Biochem Cell Biol. 2012 Mar;44(3):563-9.
29. Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, Nguyen Ie B, Jagannathan J, Laquaglia M, Winter G, Diamond M, Hou C, Attiyeh EF, Mosse YP, Pineros V, Dizin E, Zhang Y, Asgharzadeh S, Seeger RC, **Capasso M,** Pawel BR, Devoto M,

Hakonarson H, Rappaport EF, Irminger-Finger I, Maris JM. Common variation at BARD1 results in the expression of the oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res. 2012 Apr;72(8);2068-78.

30. Diskin SJ, **Capasso M**, Schnepp RW, Cole KA, Attiyeh EF, Hou C, Diamond M, Carpenter EL, Winter C, Lee H, Jagannathan J, Latorre V, Iolascon A, Hakonarson H, Devoto M, Maris JM. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet. 2012 Oct;44(10):1126-30.
31. **Capasso M**, Diskin S, Totaro F, Longo L, De Mariano M, Russo R, Cimmino F, Hakonarson H, Tonini GP, Devoto M, Maris JM, Iolascon A. Replication of gwas-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis. 2013 Jan 12.
32. De Rosa A, Monaco ML, **Capasso M**, Forestieri P, Pilone V, Nardelli C, Buono P, Daniele A. Adiponectin oligomers as potential indicators of adipose tissue improvement in obese subjects. Eur J Endocrinol. 2013 Jun 1;169(1):37-43
33. Keller S, Angrisano T, Florio E, Pero R, Decaussin-Petrucci M, Troncone G, **Capasso M**, Lembo F, Fusco A, Chiariotti L. DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. Oncol Lett. 2013 Jul;6(1):86-90. Epub 2013 Apr 18.
34. Francesca Totaro, Flora Cimmino, Piero Pignataro, Giovanni Acierno, Marilena De Mariano, Luca Longo, Gian Paolo Tonini, Achille Iolascon, **Mario Capasso.** Impact of Interleukin-6 –174 G/C Gene Promoter Polymorphism on Neuroblastoma. 21 Oct 2013 | PLOS ONE10.1371/journal.pone.0076810.
35. Barbieri E, De Preter K, **Capasso M,** Johansson P, Man TK, Chen Z, Stowers P, Tonini GP, Speleman F, Shohet JM A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma. PLoS One. 2013 Nov 19;8(11):e79843.
36. Diskin SJ, **Capasso M**, Diamond M, Oldridge DA, Conkrite K, Bosse KR, Russell MR, Iolascon A, Hakonarson H, Devoto M, Maris JM. Rare Variants in TP53 and Susceptibility to Neuroblastoma. J Natl Cancer Inst. 2014 Apr 1;106(4).
37. Barbieri E, De Preter K, **Capasso M**, Chen Z, Hsu DM, Tonini GP, Lefever S, Hicks J, Versteeg R, Pession A, Speleman F, Kim ES, Shohet JM. Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. Cancer Res. 2014 Feb 1;74(3):765-74.

38. **Capasso M**, Calabrese FM, Iolascon A, Mellerup E. Combinations of genetic data in a study of neuroblastoma risk genotypes. Cancer Genet. Mar;207(3):94-7
39. Scudiero O, Monaco ML, Nigro E, **Capasso M**, Guida M, Di Spiezio Sardo A, Prezioso D, Daniele A, Castaldo G. Mannose-binding lectin genetic analysis: possible protective role of the HYPA haplotype in the development of recurrent urinary tract infections in men. International Journal of Infectious Diseases. 2014 Feb;19:100-2.
40. Urru SA, Tandurella I, **Capasso M**, Usala E, Baronciani D, Giardini C, Visani G, Angelucci E. Reproducibility of liver iron concentration measured on a biopsy sample: A validation study in vivo. Am J Hematol. 2015 Feb;90(2):87-90. doi: 10.1002/ajh.23878.
41. **Capasso M**, Diskin SJ, Cimmino F, Acierno G, Totaro F, Petrosino G, Pezone L, Diamond M, McDaniel L, Hakonarson H, Iolascon A, Devoto M, Maris JM. Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res. 2014 1;74(23):6913-24. doi: 10.1158/0008-5472
42. Berni Canani R, Paparo L, Nocerino R, Cosenza L, Pezzella V, Di Costanzo M, **Capasso M**, Del Monaco V, D'Argenio V, Greco L, Salvatore F. Differences in DNA methylation profile of Th1 and Th2 cytokine genes are associated with tolerance acquisition in children with IgE-mediated cow's milk allergy.Clin Epigenetics. 2015; 7(1):38. doi: 10.1186/s13148-015-0070-8
43. Cimmino F, Pezone L, Avitabile M, Acierno G, Andolfo I, **Capasso M**, Iolascon A. Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells. Sci Rep. 2015 5:11158.
44. Oldridge DA, Wood A, Weichert-Leahey N, Crimmins I, Sussman R, Winter C, McDaniel LD, Diamond M, Hart LS, Zhu S, Durbin AD, Abraham BJ, Anders L, Tian L, Zhang S, Wei JS, Khan J, Bramlett K, Rahman N, **Capasso M,** Iolascon A, Gerhard Ds, Guidry Auvil JM, Young R, Hakonarson H, Diskin SJ, Thomas Look A, Maris JM. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature. 2015. 528(7582):418-21.
45. Lasorsa VA, Formicola D, Pignataro P, Cimmino F, Calabrese FM, Mora J, Esposito MR, Pantile M, Zanon C, De Mariano M, Longo L, Hogarty MD, de Torres C, Tonini GP, Iolascon A, **Capasso M.** Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget. 2016 Mar 18. doi: 10.18632/oncotarget.8187.

46. Cimmino F, Avitabile M, Pezone L, Scalia G, Montanaro D, Andreozzi M, Terracciano L, Iolascon A, **Capasso M**. CD55 is a HIF-2α marker with anti-adhesive and pro-invading properties in neuroblastoma. Oncogenesis. 2016 Apr 4;5:e212.
47. Targhetta C, Baronciani D, **Capasso M**, Depau C, Tandurella I, Giuseppina Corona M, Angelucci E. Reproducibility of liver iron concentration measured on a biopsy sample: a validation study in vivo.Am J Hematol. 2016 Feb;91(2):E7-8
48. Formicola D, Petrosino G, Lasorsa VA, Pignataro P, Cimmino F, Vetrella S, Longo L, Tonini GP, Oberthuer A, Iolascon A, Fischer M, **Capasso M**. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. J Transl Med. 2016 May 17;14(1):142.
49. Calabrese FM, Clima R, Pignataro P, Lasorsa VA, Hogarty MD, Castellano A, Conte M, Tonini GP, Iolascon A, Gasparre G, **Capasso M**. A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma. Oncotarget. Oncotarget. 2016 Aug 2;7(31):49246-49258.
50. Cimmino F, Pezone L, Avitabile M, Persano L, Vitale M, Sassi M, Bresolin S, Serafin V, Zambrano N, Scaloni A, Basso G, Iolascon A**, Capasso M**. Proteomic alterations in response to Hypoxia Inducible Factor 2α in normoxic Neuroblastoma cells. J Proteome Res. 2016. Oct 7;15(10):3643-3655.
51. Martone D, Giacobbe M, Capobianco A, Imperlini E, Mancini A, **Capasso M**, Buono P, Orrù S. Exercise intensity and technical demands of small-sided soccer games for under-12 and under-14 players: effect of area per player. J STRENGTH COND RES 2016 Aug; :
52. Marotta V, Sciammarella C, **Capasso M**, Testori A, Pivonello C, Chiofalo MG, Pivonello R, Pezzullo L, Botti G, Colao A, Faggiano A. Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine doi: 10.1007/s12020-016-1200-6.
53. Ambrosio S, Amente S, Saccà CD, **Capasso M**, Calogero RA, Lania L, Majello B. LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene. Oncotarget. 2017 Jan 17;8(3):3854-3869. doi: 10.18632/oncotarget.12924.
54. Marotta V, Sciammarella C, **Capasso M**, Testori A, Pivonello C, Chiofalo MG, Gambardella C, Grasso M, Antonino A, Annunziata A, Macchia PE, Pivonello R, Santini L, Botti G, Losito S, Pezzullo L, Colao A, Faggiano A. Germline polymorphisms of the

VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer. J Clin Endocrinol Metab. 2017 Feb 1;102(2):661-671. doi: 10.1210/jc.2016-2555.

55. McDaniel LD, Conkrite KL, Chang X, **Capasso M**, Vaksman Z, Oldridge DA, Zachariou A, Horn M, Diamond M, Hou C, Iolascon A, Hakonarson H, Rahman N, Devoto M, Diskin SJ. PLoS Genet. 2017 May 8;13(5):e1006787. doi: 10.1371/journal.pgen.1006787. eCollection 2017 May.
56. Pignataro P, Pezone L, Di Gioia G, Franco D, Iaccarino G, Iolascon A, Ciccarelli M, **Capasso M**. Association Study Between Coronary Artery Disease and rs1333049 Polymorphism at 9p21.3 Locus in Italian Population. J Cardiovasc Transl Res. 2017 Jun 21.
57. **Capasso M**, McDaniel LD, Cimmino F, Cirino A, Formicola D, Russell MR, Raman P, Cole KA, Diskin SJ. The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma. J Cell Mol Med. 2017 Dec;21(12):3224-3230.
58. Pecoraro A, Nigro E, Polito R, Monaco ML, Scudiero O, Mormile I, Cesoni Marcelli A, **Capasso M**, Habetswallner F, Genovese A, Daniele A, Spadaro G. Total and High Molecular Weight Adiponectin Expression Is Decreased in Patients with Common Variable Immunodeficiency: Correlation with Ig Replacement Therapy. Front Immunol. 2017 Jul 31;8:895.
59. Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C, Koster J, Casale F, Raia M, Viola G, Fischer M, Iolascon A, **Capasso M**. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients. Carcinogenesis. 2017 Oct 1;38(10):1011-1020.
60. Romano S, Simeone E, D'Angelillo A, D'Arrigo P, Russo M, **Capasso M**, Lasorsa VA, Zambrano N, Ascierto PA, Romano MF. FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy. Cancer Immunol Immunother. 2017 Sep;66(9):1143-1151.
61. De Falco L, Tortora R, Imperatore N, Bruno M, **Capasso M**, Girelli D, Castagna A, Caporaso N, Iolascon A, Rispo A. The role of TMPRSS6 and HFE variants in iron deficiency anemia in celiac disease. Am J Hematol. 2018 Mar;93(3):383-393.
62. Cimmino F, Formicola D, **Capasso M**. Dualistic Role of BARD1 in Cancer. Genes (Basel). 2017 Dec 8;8(12).
63. Sime W, Niu Q, Abassi Y, Masoumi KC, Zarrizi R, Køhler JB, Kjellström S, Lasorsa VA, **Capasso M**, Fu H, Massoumi R. BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma. Cell Death Dis. 2018 Apr 24;9(5):458

64. Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, **Capasso M**, Quattrone A, Tonini GP, Longo L. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy. Mol Cancer Ther. 2018 Jul;17(7):1405-1415.
65. Cimmino F, Avitabile M, Diskin SJ, Vaksman Z, Pignataro P, Formicola D, Cardinale A, Testori A, Koster J, de Torres C, Devoto M, Maris JM, Iolascon A, **Capasso M.** Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. Int J Cancer. 2018 Dec 1;143(11):2828-2837
66. Esposito MR, Binatti A, Pantile M, Coppe A, Mazzocco K, Longo L, Capasso M, Lasorsa VA, Luksch R, Bortoluzzi S, Tonini GP. Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease. Int J Cancer. 2018 Nov 15;143(10):2525-2536.
67. Cimmino F, Avitabile M, Lasorsa VA, Montella A, Pezone L, Cantalupo S, Visconte F, Corrias MV, Iolascon A, **Capasso M**. HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia. BMC Med Genet. 2019 Feb 26;20(1):37.
68. Gambale A, Russo R, Andolfo I, Quaglietta L, De Rosa G, Contestabile V, De Martino L, Genesio R, Pignataro P, Giglio S, **Capasso M**, Parasole R, Pasini B, Iolascon A. Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition. Clin Genet. 2019 Oct;96(4):359-365.
69. Testori A, Lasorsa VA, Cimmino F, Cantalupo S, Cardinale A, Avitabile M, Limongelli G, Russo MG, Diskin S, Maris J, Devoto M, Keavney B, Cordell HJ, Iolascon A, **Capasso M**. Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease. Genes (Basel). 2019 Aug 30;10(9).
70. Avitabile M, Succoio M, Testori A, Cardinale A, Vaksman Z, Lasorsa VA, Cantalupo S, Esposito M, Cimmino F, Montella A, Formicola D, Koster J, Andreotti V, Ghiorzo P, Romano MF, Staibano S, Scalvenzi M, Ayala F, Hakonarson H, Corrias MV, Devoto M, Law MH, Iles MM, Brown K, Diskin S, Zambrano N, Iolascon A, **Capasso M**. Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene. Carcinogenesis. 2019 Sep 7. pii: bgz153. doi: 10.1093/carcin/bgz153.
71. Testori A, Lasorsa VA, Cimmino F, Cantalupo S, Cardinale A, Avitabile M, Limongelli G, Russo MG, Diskin S, Maris J, Devoto M, Keavney B, Cordell HJ, Iolascon A, **Capasso M**.

Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease. Genes (Basel). 2019 Aug 30;10(9). pii: E663.

72. Passariello A, Errico ME, Donofrio V, Maestrini M, Zerbato A, Cerchia L, Capasso M, **Capasso M**, Fedele M. PATZ1 Is Overexpressed in Pediatric Glial Tumors and Correlates with Worse Event-Free Survival in High-grade Gliomas. Cancers (Basel). 2019 Oct 11;11(10).
73. Amoroso L, Ognibene M, Morini M, Conte M, Di Cataldo A, Tondo A, D'Angelo P, Castellano A, Garaventa A, Lasorsa VA, Podestà M, **Capasso M**, Pezzolo A Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients. Genes Chromosomes Cancer. 2019 Nov 22.
74. **Capasso M**, Lasorsa VA, Cimmino F, Avitabile M, Cantalupo S, Montella A, De Angelis B, Morini M, de Torres C, Castellano A, Locatelli F, Iolascon A. Transcription factors involved in tumorigenesis are over-represented in mutated active DNA binding sites in neuroblastoma. Cancer Res. 2019 Nov 29. pii: canres.2883.2019.